London
08048030295
+917498304432

Lorlatinib tablets for ALK-positive lung cancer. Advanced targeted therapy for resistant NSCLC.

LuciLorla is used in advanced ALK-positive lung cancer, especially after other treatments fail.

Active Ingredient

Lorlatinib is a third-generation ALK inhibitor.

Uses of LuciLorla

• ALK-positive NSCLC

How LuciLorla Works

Blocks ALK mutations and resistance pathways.

How to Use LuciLorla

• Take once daily

Possible Side Effects

• Weight gain
• Mood changes

Precautions

• Monitor cholesterol

Safety Information

Use under supervision.

Storage

• Store at room temperature
• Keep away from moisture
• Keep out of reach of children

 2026-03-19T05:21:55

Other Pages

View all pages